Trilogy Global Advisors LP purchased a new stake in Celgene Corporation (NASDAQ:CELG) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 201,184 shares of the biopharmaceutical company’s stock, valued at approximately $26,128,000.

Several other institutional investors have also made changes to their positions in the stock. Thompson Davis & CO. Inc. boosted its holdings in Celgene Corporation by 5.9% in the 2nd quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock worth $100,000 after buying an additional 43 shares during the last quarter. Motco boosted its holdings in Celgene Corporation by 19.3% in the 2nd quarter. Motco now owns 981 shares of the biopharmaceutical company’s stock worth $127,000 after buying an additional 159 shares during the last quarter. Penserra Capital Management LLC acquired a new stake in Celgene Corporation in the 2nd quarter worth about $129,000. Acropolis Investment Management LLC acquired a new stake in Celgene Corporation in the 2nd quarter worth about $144,000. Finally, Mitsubishi UFJ Securities Holdings Co. Ltd. boosted its holdings in Celgene Corporation by 47.5% in the 1st quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,180 shares of the biopharmaceutical company’s stock worth $147,000 after buying an additional 380 shares during the last quarter. Hedge funds and other institutional investors own 79.48% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Trilogy Global Advisors LP Purchases New Position in Celgene Corporation (CELG)” was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another site, it was illegally copied and republished in violation of United States & international copyright laws. The correct version of this article can be read at https://www.thecerbatgem.com/2017/11/24/trilogy-global-advisors-lp-purchases-new-position-in-celgene-corporation-celg.html.

In other news, Director Michael D. Casey sold 9,250 shares of Celgene Corporation stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $139.03, for a total transaction of $1,286,027.50. Following the sale, the director now owns 9,250 shares of the company’s stock, valued at approximately $1,286,027.50. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Terrie Curran sold 1,727 shares of Celgene Corporation stock in a transaction that occurred on Monday, September 25th. The shares were sold at an average price of $143.89, for a total transaction of $248,498.03. Following the sale, the insider now directly owns 3,925 shares in the company, valued at approximately $564,768.25. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 20,227 shares of company stock worth $2,843,956. Corporate insiders own 0.95% of the company’s stock.

Celgene Corporation (CELG) opened at $105.16 on Friday. The firm has a market capitalization of $82,794.26, a P/E ratio of 16.43, a PEG ratio of 0.81 and a beta of 1.79. Celgene Corporation has a twelve month low of $94.55 and a twelve month high of $147.17. The company has a current ratio of 3.65, a quick ratio of 3.52 and a debt-to-equity ratio of 1.31.

Celgene Corporation (NASDAQ:CELG) last issued its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.87 by $0.04. The business had revenue of $3.29 billion for the quarter, compared to analysts’ expectations of $3.42 billion. Celgene Corporation had a return on equity of 63.80% and a net margin of 27.36%. The business’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.58 EPS. research analysts predict that Celgene Corporation will post 6.67 earnings per share for the current year.

Several equities research analysts recently issued reports on the company. Cann reiterated a “buy” rating and issued a $166.00 price objective on shares of Celgene Corporation in a report on Wednesday. TheStreet cut Celgene Corporation from a “b-” rating to a “c+” rating in a report on Friday, November 17th. BMO Capital Markets lifted their price objective on Celgene Corporation from $148.00 to $155.00 and gave the stock an “outperform” rating in a report on Friday, November 17th. Canaccord Genuity set a $140.00 price objective on Celgene Corporation and gave the stock a “buy” rating in a report on Thursday, November 16th. Finally, Oppenheimer Holdings, Inc. set a $166.00 price objective on Celgene Corporation and gave the stock a “buy” rating in a report on Thursday, November 16th. One research analyst has rated the stock with a sell rating, eleven have given a hold rating, nineteen have issued a buy rating and two have assigned a strong buy rating to the company. Celgene Corporation presently has a consensus rating of “Buy” and an average target price of $139.57.

Celgene Corporation Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Stock Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related stocks with our FREE daily email newsletter.